Joseph Schwartz
Stock Analyst at Leerink Partners
(4.09)
# 501
Out of 5,152 analysts
154
Total ratings
34.78%
Success rate
20.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Joseph Schwartz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GOSS Gossamer Bio | Downgrades: Market Perform | $6 → $1 | $0.58 | +72.41% | 8 | Feb 24, 2026 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Outperform | $80 → $70 | $21.80 | +221.10% | 7 | Dec 30, 2025 | |
| FOLD Amicus Therapeutics | Downgrades: Market Perform | $17 → $15 | $14.33 | +1.19% | 13 | Dec 29, 2025 | |
| SPRB Spruce Biosciences | Upgrades: Outperform | $160 | $57.54 | +178.07% | 7 | Dec 3, 2025 | |
| DSGN Design Therapeutics | Upgrades: Outperform | $7 → $14 | $10.37 | +35.00% | 5 | Dec 3, 2025 | |
| IFRX InflaRx | Downgrades: Market Perform | $5 → $2 | $0.92 | +118.48% | 5 | Dec 3, 2025 | |
| BMRN BioMarin Pharmaceutical | Downgrades: Market Perform | $82 → $60 | $60.43 | -0.71% | 11 | Dec 3, 2025 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Market Perform | $15 → $16 | $15.04 | +6.38% | 7 | Dec 3, 2025 | |
| QURE uniQure | Maintains: Outperform | $68 → $60 | $9.04 | +563.72% | 3 | Nov 10, 2025 | |
| MNPR Monopar Therapeutics | Initiates: Outperform | $115 | $55.49 | +107.24% | 1 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $39.51 | +122.73% | 2 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $12 → $15 | $16.09 | -6.77% | 14 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $20 | $16.37 | +22.17% | 6 | Jul 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $115 | $149.88 | -23.27% | 4 | Jun 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $4 → $12 | $8.35 | +43.71% | 4 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $46.48 | -39.76% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $40 | $28.18 | +41.94% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $1.34 | - | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $12 | $6.14 | +95.44% | 6 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $8 | $0.41 | +1,831.90% | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $48 | $64.29 | -25.34% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $18 | $26.80 | -32.84% | 5 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $33 → $34 | $79.45 | -57.21% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $148 → $163 | $241.38 | -32.47% | 15 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $33 | $6.76 | +388.17% | 2 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $64 → $52 | $10.24 | +407.81% | 5 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $30 | $28.88 | +3.88% | 2 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $30 | $94.83 | -68.36% | 6 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $10 → $12 | $1.70 | +605.88% | 2 | Sep 26, 2017 |
Gossamer Bio
Feb 24, 2026
Downgrades: Market Perform
Price Target: $6 → $1
Current: $0.58
Upside: +72.41%
Ultragenyx Pharmaceutical
Dec 30, 2025
Maintains: Outperform
Price Target: $80 → $70
Current: $21.80
Upside: +221.10%
Amicus Therapeutics
Dec 29, 2025
Downgrades: Market Perform
Price Target: $17 → $15
Current: $14.33
Upside: +1.19%
Spruce Biosciences
Dec 3, 2025
Upgrades: Outperform
Price Target: $160
Current: $57.54
Upside: +178.07%
Design Therapeutics
Dec 3, 2025
Upgrades: Outperform
Price Target: $7 → $14
Current: $10.37
Upside: +35.00%
InflaRx
Dec 3, 2025
Downgrades: Market Perform
Price Target: $5 → $2
Current: $0.92
Upside: +118.48%
BioMarin Pharmaceutical
Dec 3, 2025
Downgrades: Market Perform
Price Target: $82 → $60
Current: $60.43
Upside: -0.71%
Aurinia Pharmaceuticals
Dec 3, 2025
Downgrades: Market Perform
Price Target: $15 → $16
Current: $15.04
Upside: +6.38%
uniQure
Nov 10, 2025
Maintains: Outperform
Price Target: $68 → $60
Current: $9.04
Upside: +563.72%
Monopar Therapeutics
Nov 10, 2025
Initiates: Outperform
Price Target: $115
Current: $55.49
Upside: +107.24%
Sep 29, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $39.51
Upside: +122.73%
Sep 9, 2025
Maintains: Market Perform
Price Target: $12 → $15
Current: $16.09
Upside: -6.77%
Jul 7, 2025
Maintains: Outperform
Price Target: $18 → $20
Current: $16.37
Upside: +22.17%
Jun 10, 2025
Maintains: Outperform
Price Target: $100 → $115
Current: $149.88
Upside: -23.27%
May 23, 2025
Upgrades: Outperform
Price Target: $4 → $12
Current: $8.35
Upside: +43.71%
Feb 25, 2025
Initiates: Outperform
Price Target: $28
Current: $46.48
Upside: -39.76%
Oct 11, 2024
Maintains: Outperform
Price Target: $20 → $40
Current: $28.18
Upside: +41.94%
Jul 3, 2024
Upgrades: Outperform
Price Target: n/a
Current: $1.34
Upside: -
Jun 24, 2024
Upgrades: Outperform
Price Target: $12
Current: $6.14
Upside: +95.44%
Jun 20, 2024
Maintains: Outperform
Price Target: $6 → $8
Current: $0.41
Upside: +1,831.90%
Mar 17, 2023
Initiates: Market Perform
Price Target: $48
Current: $64.29
Upside: -25.34%
Feb 3, 2023
Maintains: Outperform
Price Target: $20 → $18
Current: $26.80
Upside: -32.84%
Feb 3, 2023
Maintains: Market Perform
Price Target: $33 → $34
Current: $79.45
Upside: -57.21%
Jan 17, 2023
Maintains: Outperform
Price Target: $148 → $163
Current: $241.38
Upside: -32.47%
Nov 10, 2022
Maintains: Outperform
Price Target: $40 → $33
Current: $6.76
Upside: +388.17%
Aug 5, 2022
Downgrades: Market Perform
Price Target: $64 → $52
Current: $10.24
Upside: +407.81%
May 12, 2022
Maintains: Outperform
Price Target: $34 → $30
Current: $28.88
Upside: +3.88%
May 5, 2022
Maintains: Outperform
Price Target: $50 → $30
Current: $94.83
Upside: -68.36%
Sep 26, 2017
Maintains: Outperform
Price Target: $10 → $12
Current: $1.70
Upside: +605.88%